Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting

Data presented support the potential of combining oncolytic virotherapy along with PM21-NK cell adoptive therapy against lung cancer Amsterdam, The Netherlands, November 12, 2020 – Kiadis Pharma N.V....
November 02, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Sanofi offers to acquire Kiadis for €308 million

This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of...
October 26, 2020 02:00 ET | Source: Kiadis Pharma N.V.

Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting

Amsterdam, The Netherlands, October 26, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
October 01, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis announces the placement of €5 million convertible bonds with Kreos

9% secured convertible bonds replace €5 million in Kreos debtConversion price €2 per share Remaining Kreos debt facilities reduced to €1.6 million Amsterdam, The Netherlands, October 1, 2020 –...
September 30, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs

K-NK002 (HSCT): IND approved to enter Phase 2 development K-NK003 (AML R/R): IND approved and multiple patients enrolled for Phase 1 investigator initiated trial for treatment of relapsed/refractory...
September 28, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis and Gulf Coast Regional Blood Center announce collaboration to provide universal donor material for K-NK cell therapy programs

Collaboration marks first contractual partnership with supplier of universal donor material Amsterdam, The Netherlands, September 28, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company")...
September 15, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis receives $9.5 million from the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program to fund Kiadis K-NK cell COVID-19 therapy

Funding for COVID-19 research and development program (K-NK-ID101), to investigate the potential to establish it as a universal countermeasure to fight COVID-19 and future pandemicsFunding obtained...
September 14, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis announces U.S. FDA approval of the Abigail Wexner Research Institute at Nationwide Children’s Hospital’s IND for a COVID-19 clinical trial with off-the-shelf K-NK cells using Kiadis’ proprietary platforms

Amsterdam, The Netherlands, September 14, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative...
September 03, 2020 01:00 ET | Source: Kiadis Pharma N.V.

Kiadis announces investor events for September 2020

Company announces Notice of Results for the six months ended June 30, 2020 Amsterdam, The Netherlands, September 3, 2020 – Kiadis Pharma N.V. (“Kiadis” or...
August 29, 2020 06:30 ET | Source: Kiadis Pharma N.V.

Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)

New data will be presented in an e-poster today at the Virtual Edition of the 46th EBMT Annual Meeting Amsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)...